Navigation Links
Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
Date:10/23/2010

se inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, and thus allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), advanced age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. Increasing incidence, higher treatment failures and recurrence with current therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials. Learn more about CDI at www.cdiinfo.org.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA to the EMA (Europe) for fidaxomicin.  Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. We plan to have an NDA submitted to the FDA in the first quarter of 2011.
Additional information can be found at http://
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pa. , Sept. 18, 2014  Iliad Neurosciences, ... approaches to diagnosing and treating Autism Spectrum Disorders (ASD) ... License Agreement with The Research Foundation for The State ... Iliad will provide a new biomarker to identify an ... susceptibility to ASD. This biomarker is expected to be ...
(Date:9/18/2014)... 18, 2014  Decision Resources Group finds that Regeneron,s ... (VEGF) agent for wet AMD, is equally likely to ... Genentech,s Lucentis, which is the standard of care for ... (MCO) directors do not identify a clear clinical or ... than Lucentis to be listed on tier 1 or ...
(Date:9/18/2014)... MARIETTA, Ga. , Sept. 18, 2014 /PRNewswire/ ... ), an integrated developer, processor and marketer of ... human amniotic membrane, announced today that it has ...  Through the agreement, MiMedx will provide its dehydrated ... to be marketed non- exclusively on a private ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3
... 30 A partnership announced today between Medical City Hospital ... of potential life-saving technology, as Medical City recently helped outfit all ... devices. , , ... The LIFENET device, a unique combination of web, broadband and medical ...
... LONDON , NEW YORK and HAMILTON, Bermuda , ... private equity firm focused on the biotechnology and pharmaceutical industries, announced today ... TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also ... , , ...
Cached Medicine Technology:Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 2Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 3Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 4Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 5Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the ... of its Fiber Transport Services, adding Point of Presence ... establishing a PoP at Cermak, IFN enables interconnect opportunities ... high bandwidth fiber transport service to US and Global ... President of Sales and Marketing August Zehner, establishing a ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered with ... Coach Christi Hall to campus. , Hall’s journey to a ... gaining weight as a result of years of medication. Through ... nutrition. One year later she had lost 50 pounds, lowered ... and cardio. , After joining the YMCA staff, she furthered ...
(Date:9/19/2014)... Newport News, Va. (PRWEB) September 19, 2014 ... at Warwick Forest, a skilled nursing center that offers rehabilitation ... But they will this weekend when a young couple marries ... together and with their combined 140 years of marriage have ... , Sarah Horky, 18, and Dan Eads, 20, may ...
(Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
(Date:9/18/2014)... OR (PRWEB) September 18, 2014 Active ... 50 and older as fully participating members of society ... lifestyle. To celebrate, The Stafford – a boutique retirement ... 97034 – will host two screenings of Cyber-Seniors - ... excited for our residents to watch this great film,” ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 2Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 3Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
... leaders in diagnosing and treating Lyme disease, has launched a new website ... treatment and cure of this highly debated disease. , ... Havertown, PA ... launched a new web site today that is dedicated to giving advanced, ...
... been named president of RetireSafe, a national bipartisan, non-profit ... the options and benefits of retired and retiring Americans ... He has served as a member of the ... providing leadership in multiple areas that engage all facets ...
... patient-centered CERWASHINGTON, May 19 Joining ... the New Democrat Coalition, Tony Coelho, chairman of ... with reporters and announced PIPC,s support for the ... an important step forward for patients and caregivers, ...
... small study , , TUESDAY, May 19 (HealthDay News) -- ... restored blood flow to hearts with blocked arteries for ... reported. , "I think this is very good news ... line and have no options left," said Dr. Douwe ...
... /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of ... its primary supplier, Atomic Energy of Canada Limited ... medical isotopes, primarily molybdenum-99 (Mo-99) used in the ... MDS Nordion that they anticipate the National Research ...
... First, New York State nonprofit outpatient clinics ... Medicaid, Medicaid managed care, Medicare, and insurance billing ... healthiest organization. Millin Associates ( www.millinmedical.com ... for 27 years, provides expanded services and next-generation ...
Cached Medicine News:Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 2Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 3Health News:RetireSafe Names Thair Phillips as President 2Health News:PIPC Supports New Comparative Effectiveness Research (CER) Bill 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 3Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 2Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 3Health News:Nonprofit Outpatient Clinics and Social Service Agencies Outsource Billing to Increase Profits 2
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: